DaVitri is an automated egg-freezing platform that enables fertility clinics to standardize one of the most technically demanding steps in IVF. It allows both small and large centralized laboratories to process significantly more procedures while supporting nation’s embryologists.
For the first time in India, couples seeking In Vitro Fertilisation treatment can access an advanced, automated egg-freezing technology to support successful pregnancies and healthy births. Hana Health by DSS Imagetech, a leader in molecular diagnostics, life sciences, and biotechnology, has partnered exclusively with Overture Life, a pioneer in automated IVF technologies, to introduce their DaVitri platform to Indian fertility clinics. Overture Life is recognized as the first company to achieve live births through both robotic fertilization and robotic egg freezing. The DaVitri system has received regulatory clearance in the United States, the United Kingdom, and Europe, allowing clinics to standardize egg-freezing procedures, one of the most technically challenging steps in IVF, while expanding capacity and supporting embryologists amid growing patient demand in India.
Health Technology Insights: Corus Orthodontists Secures C$20 Million Equity Investment
Ashim Ghatak, Senior Vice President of the IVF Division at Hana Health by DSS, explained that DaVitri resolves a critical bottleneck in embryology that has historically limited scale and reproducibility. He noted that every IVF cycle represents significant hope, emotional investment, and financial commitment for patients. Automation ensures consistent vitrification using data-driven protocols, which improves predictability, enhances embryo yield, and reduces the need for repeated cycles. Variability during egg freezing and warming has long contributed to inconsistent outcomes and additional cycles, which are both emotionally and financially taxing for patients. DaVitri addresses this challenge by automating vitrification through a regulated microfluidic system, giving clinics the ability to reduce variability and deliver reliable results to couples seeking fertility treatment.
Hans Gangeskar, Chief Executive Officer of Overture Life, highlighted that India’s fertility clinics are under intense pressure due to a growing and diverse patient population. He stated that DaVitri allows clinics to scale efficiently while maintaining clinical standards and consistency. The collaboration offers Indian clinics access to a service-supported, modernized IVF workflow capable of meeting higher patient demand without compromising quality. Clinical evaluations have shown that DaVitri improves post-thaw embryo development compared with manual methods and allows both large and small laboratories to process significantly more procedures without increasing staff. By reducing infrastructure costs from millions of dollars to a more accessible level, the system enables smaller clinics and satellite centers to provide advanced IVF services that were previously unattainable.
Dr. Hrishikesh Pai, Medical Director at Bloom IVF and CEO of WAGO, added that automation represents the future of IVF, and the microfluidics technology behind DaVitri marks a major advancement in precision and efficiency for cryopreservation. He emphasized that this innovation brings predictability, quality, and scale to fertility care in India, improving patient access to cutting-edge reproductive technology.
Health Technology Insights: SEQSTER Expands Partnership with Praxis Precision Medicines
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
